(Q35813657)

10 August 2017

1 reference

title

Inflammation in atherosclerosis and diabetes mellitus (English)

1 reference

10 August 2017

1 reference

Jorge Plutzky

1

1 reference

10 August 2017

1 August 2004

1 reference

Reviews in Endocrine and Metabolic Disorders

10 August 2017

1 reference

10 August 2017

5

1 reference

10 August 2017

3

1 reference

10 August 2017

255-259

1 reference

https://scigraph.springernature.com/pub.10.1023/b:remd.0000032414.17672.5c

10 August 2017

0 references

cites work

Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes

1 reference

12 December 2020

The PPARs: from orphan receptors to drug discovery

1 reference

12 December 2020

Diabetes and cardiovascular disease. The "common soil" hypothesis

1 reference

12 December 2020

Insulin resistance and cardiovascular disease

1 reference

12 December 2020

beta-Cell death during progression to diabetes

1 reference

12 December 2020

Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes

1 reference

12 December 2020

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control

1 reference

12 December 2020

Obesity, adiponectin and vascular inflammatory disease

1 reference

12 December 2020

Peroxisome proliferator-activated receptors

1 reference

12 December 2020

The prevention or delay of type 2 diabetes

1 reference

12 December 2020

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

12 December 2020

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

1 reference

12 December 2020

Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension

1 reference

12 December 2020

Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets

1 reference

12 December 2020

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

1 reference

12 December 2020

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes

1 reference

12 December 2020

Adiponectin: systemic contributor to insulin sensitivity

1 reference

12 December 2020

Atherosclerosis. the road ahead

1 reference

12 December 2020

Chemokines--chemotactic cytokines that mediate inflammation

1 reference

12 December 2020

Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells

1 reference

12 December 2020

C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?

1 reference

12 December 2020

Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease

1 reference

12 December 2020

Changing concepts of atherogenesis

1 reference

12 December 2020

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

1 reference

12 December 2020

Inflammation and emerging risk factors in diabetes mellitus and atherosclerosis

1 reference

12 December 2020

The role of immune and inflammatory processes in the development of macrovascular disease in diabetes

1 reference

12 December 2020

Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones

1 reference

12 December 2020

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

1 reference

12 December 2020

PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation

1 reference

12 December 2020

Inflammation and atherosclerosis

1 reference

12 December 2020

MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B.

1 reference

12 December 2020

1 reference

12 December 2020

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

12 December 2020

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

1 reference

12 December 2020

Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis

1 reference

12 December 2020

Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation

1 reference

12 December 2020

Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease

1 reference

12 December 2020

Diabetic macrovascular disease: the glucose paradox?

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells

1 reference

12 December 2020

Atherosclerosis — An Inflammatory Disease

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

1 reference

12 December 2020

Inflammatory markers and coronary heart disease

1 reference

12 December 2020

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

1 reference

12 December 2020

Connecting the role of C-reactive protein and statins in cardiovascular disease

1 reference

12 December 2020

NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?

1 reference

12 December 2020

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

1 reference

12 December 2020

Inflammatory bio-markers and cardiovascular risk prediction

1 reference

12 December 2020

Prevention of type 2 diabetes

1 reference

12 December 2020

Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice

1 reference

12 December 2020

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

1 reference

12 December 2020

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

1 reference

12 December 2020

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis

1 reference

12 December 2020

PPARs as Therapeutic Targets: Reverse Cardiology?

1 reference

12 December 2020

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

1 reference

12 December 2020

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

1 reference

12 December 2020

Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

1 reference

12 December 2020

Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology

1 reference

12 December 2020

Peroxisome proliferator-activated receptors as therapeutic targets in inflammation

1 reference

12 December 2020

Another potential use of troglitazone in noninsulin-dependent diabetes mellitus

1 reference

12 December 2020

10.1023/B:REMD.0000032414.17672.5C

Identifiers

DOI

1 reference

PubMed ID

15211097

Dimensions Publication ID

10 August 2017

1012693314

0 references

Fatcat ID

release_sh2zswm7ujadvgy7b4i5j7oj34

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sh2zswm7ujadvgy7b4i5j7oj34

24 November 2022

mapped directly with Wikidata item

PubMed ID

15211097

1 reference

PubMed ID

15211097